TNDM
TANDEM DIABETES CARE INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 3 ▲ Gilbert Cisneros bought $1,001 - $15,000, last disclosed Apr 8
- Jun 1 ▲ Wells Fargo upgrades
- Jun 23 Deutsche Bank initiates
- Aug 21 William Blair initiates
- Sep 29 ▲ Gilbert Cisneros bought $1,001 - $15,000, last disclosed Oct 13
- Oct 7 Barclays initiates
- Oct 27 ▼ 1 insider sell $32.6K at $19.15
- Nov 5 ▲ Tandem Diabetes Care reported Q3 2026 sales of $283.7M (+14% YoY), a…
- Nov 5 ▲ Earnings: TNDM Q3 2026 Earnings: EPS $-0.1 (+59.5% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $32.6K.
- InstitutionsBULLISH
Q3 2026: 23 added (1 new), 11 trimmed or exited.
- AnalystsBULLISH
18 of 30 rate it Buy or better. Median target $25.00 (+25%).
- EstimatesFALLING
Current-quarter EPS estimate $0.179 → $0.107 over 90 days. 0 up, 4 down in 30 days.
- Short sellersSTEADY
Short interest +7.2% to 16.17M shares. 7.6 days to cover, ≈23.2% of shares.
- TrendUPTREND
15% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 27.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | ADD | $35.8M |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $28.8M |
| FMR LLC | ADD | $21.7M |
| MORGAN STANLEY | ADD | $15.9M |
| Aberdeen Group plc | TRIM | $14.0M |
| BANK OF MONTREAL /CAN/ | ADD | $12.0M |
| Qube Research & Technologies Ltd | TRIM | $7.0M |
| Jefferies Financial Group Inc. | DOUBLED | $6.9M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
30 analystsPrice is inside the target range. Median implies +25%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 6, 2026 | Barclays MAINTAIN | Equal-Weight |
| Nov 6, 2026 | Wells Fargo MAINTAIN | Overweight |
| Oct 7, 2026 | Barclays INITIATE | Equal-Weight |
| Sep 30, 2026 | Citigroup MAINTAIN | Neutral |
| Sep 24, 2026 | Truist Securities MAINTAIN | Buy |
| Aug 21, 2026 | William Blair INITIATE | Outperform |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
TWOMEY CHRISTOPHER J Director Oct 27, 2026 | EXERCISE | $32.3K |
TWOMEY CHRISTOPHER J Director Oct 27, 2026 | SELL | $32.6K |
Kyrillos Jean-Claude EVP & Chief Operating Officer Oct 15, 2026 | EXERCISE | 3,637 sh |
Kyrillos Jean-Claude EVP & Chief Operating Officer Oct 15, 2026 | TAX W/H | $31.8K |
Sheridan John F PRESIDENT & CEO Aug 15, 2026 | TAX W/H | $69.2K |
Sheridan John F PRESIDENT & CEO Aug 15, 2026 | EXERCISE | 9,934 sh |
Sheridan John F PRESIDENT & CEO Aug 15, 2026 | TAX W/H | $114.8K |
Sheridan John F PRESIDENT & CEO Aug 15, 2026 | EXERCISE | 5,982 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.11 | $0.01–$0.21 | -40.4% | $291.5M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | $0.10 | -$0.23–$0.57 | -40.1% | $1.2B |
Short side
FINRA· Oct 30, 2026SecBot reports
9 filings · 2 bullish · 1 bearish · 1 mixed · 5 neutral- BEARISH SC 13G/ANov 16, 2026
Sessa Capital IM disclosed a 0.6% passive stake in Tandem Diabetes Care as of September 30, 2026, holding 426,054 shares. This is an amendment to a prior 13G filed May 15, 2025, and represents a significant reduction from the prior stake, which was above 5%.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13GNov 16, 2026
Balyasny Asset Management disclosed a 5.21% passive stake in Tandem Diabetes Care as of September 30, 2026, holding 3,624,727 shares. This is a new 13G filing by Balyasny, which had not previously reported a 5%+ position in TNDM.
🔒 Fresh report (last 24h), subscribers only
- BULLISH 8-KNov 13, 2026
Tandem Diabetes Care received FDA 510(k) clearance for a tubeless cartridge and infusion set for…
Monitor the commercial launch timeline in H1 2027 and initial adoption rates. The tubeless feature with 7-day wear is a competitive differentiator against other tubeless pumps. Watch for competitor…
- NEUTRAL SC 13GNov 9, 2026
Goldman Sachs Group disclosed a 5.9% passive stake in Tandem Diabetes Care as of September 30…
A new 5.9% passive stake from Goldman Sachs signals institutional interest following TNDM's improving earnings trajectory. Monitor for any subsequent 13D conversion or further accumulation, though…
All TNDM filing & press-release reports (9)
- SC 13G/A reportNov 16, 2026
- SC 13G reportNov 16, 2026
- 8-K reportNov 13, 2026
- SC 13G reportNov 9, 2026
- 8-K reportNov 5, 2026
- 144 reportOct 27, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 15, 2026
- DEFA14A reportApr 7, 2026